Accordingly, more researches upon the cellular and molecular levels, like the involvement of androgen and androgen receptor pathways, are still needed to further elucidate the underlying mechanisms of XLQ in the treatment of BPH. This evidence concerns the gene AR and benign prostatic hyperplasia.